Biotech and Healthcare investors in Asia-Pacific
18 funds · Updated
Gatsbie lists 18 Biotech and Healthcare investors headquartered in Asia-Pacific (as of 2026-11-18).
Each one names both biotech & life sciences and healthcare & medtech in its investment focus.
Most are based in India (5), China (4) and Singapore (3); the most common stages are Seed (14), Series A (14) and Series B (10); the most common kinds of capital are Venture equity (16), Growth equity (4) and Debt (2).
Which Biotech and Healthcare investors are based in Asia-Pacific?
Gatsbie lists 18 Biotech and Healthcare investors headquartered in Asia-Pacific (as of 2026-11-18). Most are in India (5), China (4) and Singapore (3). They include Pix Vine Capital (Singapore), Ankur Capital (Mumbai), GRC SinoGreen Fund (Cayman Islands), IMM Investment, Corp. (Seoul), NIIF | India's premier sovereign-anchored alternative assets manager (Mumbai) and Verge Healthtech Fund (Singapore).
Which family offices invest in Biotech and Healthcare in Asia-Pacific?
3 of the 18 Biotech and Healthcare investors on Gatsbie are family offices, including CYRUS POONAWALLA GROUP (FAMILY OFFICE), ERAGON FAMILY OFFICE and JMCR Partners.
Upload your deck to see which of these fit your startup, with a written reason for each.
18 funds
Most active first: deals in the last 24 months, then portfolio companies on record.
| # | Fund | HQ | Stages | Partner emails |
|---|---|---|---|---|
| 1 | Pix Vine Capital | Singapore | Pre-Seed–Series B | 2 |
| 2 | Ankur Capital | Mumbai | Pre-Seed–Series A | 12 |
| 3 | GRC SinoGreen Fund | Cayman Islands | Series C+ | 11 |
| 4 | IMM Investment, Corp. | Seoul | Seed–Series C+ | 10 |
| 5 | NIIF | India's premier sovereign-anchored alternative assets manager | Mumbai | Growth | 6 |
| 6 | Verge Healthtech Fund | Singapore | Pre-Seed–Series A | 9 |
| 7 | Unicorn India Ventures | Mumbai | Seed, Series A | 1 |
| 8 | CYRUS POONAWALLA GROUP (FAMILY OFFICE) | Pune | Series C+, Growth | 3 |
| 9 | ERAGON FAMILY OFFICE | Mumbai | Seed–Series B, Growth | 1 |
| 10 | Ally Bridge Group | Hong Kong | Seed–Series C+ | 14 |
| 11 | LYFE Capital | Shanghai | Seed–Series B, Growth | 4 |
| 12 | Ecliptic Venture Capital | Auckland | Pre-Seed–Series B | 3 |
| 13 | JMCR Partners | Hong Kong | Seed, Series C+ | 2 |
| 14 | DigiTx Partners | Brisbane | Pre-Seed–Series A | 3 |
| 15 | Newgen Venture Partners | Shanghai | Pre-Seed–Series B | 4 |
| 16 | Ion Pacific | Hong Kong | Seed–Series B | 17 |
| 17 | Main Sequence | Sydney | Pre-Seed–Series B | 15 |
| 18 | The Hina Group | San Francisco | Series A, Series B, Growth, Mature | 9 |
Other sector pairs
Biotech and Healthcare investors elsewhere
Counted by where each fund is headquartered, from public sources, as of 2026-11-18. Only funds naming both sectors are listed.
